Table 3.
Association between clinicopathologic characteristics and metachronous colorectal adenomas.
| Logistic multivariate analyses | Negative binomial regression | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Any CRAs (n = 1,559) (vs. Absent CRA, n = 1, 345) | ≥ 3 any CRAs (n = 514) (vs. < 3, n = 2,390) | ≥ 4 any CRAs (n = 316) (vs. < 4, n = 2,588) | ≥ 5 any CRAs (n = 207) (vs. < 5, n = 2,697) | Metachronous CRAs (n = 2,904) | ||||||
| aOR (95% CI) | p value | aOR (95% CI) | p value | aOR (95% CI) | p value | aOR (95% CI) | p value | Exp (B) (95% CI) | p value | |
| Age | 1.02 (1.01–1.03) | <0.001 | 1.03 (1.02–1.05) | <0.001 | 1.30 (1.02–1.05) | <0.001 | 1.04 (1.02–1.06) | <0.001 | 1.02 (1.01–1.02) | <0.001 |
| Men | 1.87 (1.56–2.24) | <0.001 | 2.62 (1.96–3.51) | <0.001 | 2.89 (1.97–4.24) | <0.001 | 3.20 (1.92–5.32) | <0.001 | 1.68 (1.48–1.90) | <0.001 |
| Index BMI (kg/m2) | ||||||||||
| <25 | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | |||||
| 25–29 | 1.07 (0.91–1.26) | 0.432 | 1.34 (1.08–1.67) | 0.009 | 1.35 (1.03–1.77) | 0.031 | 1.46 (1.05–2.04) | 0.024 | 1.08 (0.97–1.20) | 0.158 |
| ≥30 | 1.82 (1.15–2.89) | 0.011 | 2.23 (1.31–3.80) | 0.003 | 1.93 (1.01–3.69) | 0.048 | 2.39 (1.13–5.06) | 0.023 | 1.40 (1.07–1.84) | 0.016 |
| p for trend | 0.049 | <0.001 | 0.007 | 0.004 | 0.016 | |||||
| Current smoking | 1.23 (0.99–1.52) | 0.058 | 1.25 (0.96–1.62) | 0.079 | 1.08 (0.78–1.49) | 0.638 | 1.30 (0.89–1.91) | 0.172 | 1.14 (1.00–1.30) | 0.048 |
| Family history of CRC | 1.27 (0.82–2.00) | 0.284 | 1.13 (0.62–2.08) | 0.681 | 1.16 (0.55–2.45) | 0.705 | 1.09 (0.42–2.81) | 0.860 | 1.04 (0.79–1.39) | 0.762 |
| Use of aspirin or NSAIDs | 1.08 (0.85–1.37) | 0.517 | 1.01 (0.75–1.37) | 0.956 | 1.38 (0.97–1.96) | 0.071 | 1.36 (0.89–2.08) | 0.158 | 1.05 (0.09–1.22) | 0.544 |
| Index colonoscopy | ||||||||||
| LRA | 1.00 (reference) | <0.001 | 1.00 (reference) | <0.001 | 1.00 (reference) | <0.001 | 1.00 (reference) | <0.001 | 1.00 (reference) | |
| HRA | 1.80 (1.53–2.12) | 2.29 (1.84–2.84) | 2.71 (2.06–3.56) | 2.99 (2.12–4.23) | 1.76 (1.58–1.95) | <0.001 | ||||
| Follow-up period | 1.13 (1.05–1.22) | 0.002 | 1.16 (1.05–1.29) | 0.005 | 1.16 (1.02–1.33) | 0.026 | 1.25 (1.06–1.48) | 0.008 | 1.12 (1.06–1.18) | <0.001 |
| Frequency of surveillance | 2.58 (2.11–3.16) | <0.001 | 3.10 (2.55–3.77) | <0.001 | 3.54 (2.84–4.40) | <0.001 | 3.64 (2.85–4.64) | <0.001 | 1.87 (1.71–2.06) | <0.001 |
CRA,colorectal adenoma; aOR, adjusted odds ratio; 95% CI, 95% confidence interval; BMI, body mass index; CRC, colorectal cancer; NSAIDs, nonsteroidal anti-inflammatory drugs; LRA, low risk adenoma; HRA, high risk adenoma. Hosmer-Lemeshow Goodness-of-Fit test of each model showed p = 0.552 for any CRAs, p = 0.887 for ≥3 any CRAs, p = 0.470 for ≥4 any CRAs, and p = 0.427 for ≥5 any CRAs.